Anthera Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anthera Pharmaceuticals, Inc.
Public
Traded as NASDAQANTH
Industry Pharmaceuticals
Founded 2004
Headquarters Hayward, California, U.S.
Key people
Craig Thompson
(President and CEO)
Website Anthera.com

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera’s leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy[1][2] is currently in Phase 2 clinical trial.

Products[edit]

Blisibimod[edit]

Sollpura[edit]

July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company.[8] Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.[9]

References[edit]

  1. ^ "Overview". Anthera Pharmaceuticals, Inc. Archived from the original on August 21, 2014. Retrieved August 11, 2014. 
  2. ^ "Management Team". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals, Inc. Retrieved August 11, 2014. 
  3. ^ Groom, J; Kalled, SL; Cutler, AH; Olson, C; Woodcock, SA; Schneider, P; Tschopp, J; Cachero, TG; Batten, M; Wheway, J; Mauri, D; Cavill, D; Gordon, TP; Mackay, CR; Mackay, F (Jan 2002). "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome". J Clin Invest. 109 (1): 59–68. PMC 150825Freely accessible. PMID 11781351. doi:10.1172/JCI14121. 
  4. ^ Petri, Michelle; Stohl, William; Chatham, Winn; McCune, Joseph; Chevrier, Marc; Ryel, Jeff; Recta, Virginia; Zhong, John; Freimuth, William. "ARTHRITIS & RHEUMATISM Vol. 58, No. 8, August 2008, pp 2453–2459 DOI 10.1002/art.23678 © 2008, American College of Rheumatology Association of Plasma B Lymphocyte Stimulator Levels and Disease Activity in Systemic Lupus Erythematosus" (PDF). Deepblue. American College of Rheumatology. Retrieved August 11, 2014. 
  5. ^ Zhang, J; Roschke, K; Baker, KP; Wang, Z; Alarcon, GS; Fessler, BJ; Bastian, H; Kimberly, RP; Zhou, T (2001). "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus". Journal of Immunology. J Immunol. 166 (1): 6–10. PMID 11123269. doi:10.4049/jimmunol.166.1.6. 
  6. ^ "Product Candidates". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals, Inc. Archived from the original on August 16, 2014. Retrieved August 11, 2014. 
  7. ^ Hsu, H; Khare, SD; Lee, F; Miner, K; Hu, YL; Stolina, M; Hawkins, N; Chen, Q; Ho, SY; Min, H; Xiong, F; Boone, T; Zack, DJ. "A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease". Clin Exp Rheumatol. Clinical and Experimentla Rheumatology. 30 (2): 197–201. PMID 22325420. 
  8. ^ "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Retrieved August 11, 2014. 
  9. ^ "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Retrieved August 11, 2014. 

External links[edit]